Table of Content


Chapter 1 Introduction
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst’s Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Drug Development and Approval Process
Introduction
Drug Discovery Process
Drug Definition
Drug Development Regulations
Classification of Techniques Used in Drug Discovery
High-Throughput Screening
Bioanalytical Instruments for Drug Discovery
Cell-Based Assays and Reagents for Drug Discovery
Proteomics Drug Discovery Tools
Genomics Drug Discovery Tools
Bioinformatics as a Platform for Drug Discovery
Others: Metabolomics, Combinatorial Chemistry, Systems Biology, and Nanotechnology
Chapter 4 Disease Overview
Etiology
Pathogenesis
Symptoms
Comorbidities
Risk Factors
Environmental
Genetic
Epigenetic Alterations
Aging
Chapter 5 Disease Management and Treatment
Diagnosis of Idiopathic Pulmonary Fibrosis
Diagnostic Criteria for IPF
Treatments for IPF
Lifestyle Changes
Oxygen
Medications
Pulmonary Rehabilitation
Lung Transplant
Chapter 6 Marketed Drugs for Idiopathic Pulmonary Fibrosis
Introduction
Overview of Products
Esbriet Drug Profile
Ofev Drug Profile
Chapter 7 Product Forecast for Idiopathic Pulmonary Fibrosis
Esbriet (Pirfenidone)
Ofev (Nintedanib)
Chapter 8 Product Pipeline for Idiopathic Pulmonary Fibrosis
Product Pipeline for Idiopathic Pulmonary Fibrosis
Chapter 9 Appendix: Acronyms



List of Figures


Figure 1 : Drug Discovery Process
Figure 2 : Schematic View of IPF Pathogenesis
Figure 3 : Diagnostic Algorithm for IPF
Figure 4 : Boehringer Ingelheim GmbH: Annual Revenue, 2015-2019
Figure 5 : Boehringer Ingelheim GmbH: Revenue Shares, by Business Unit, 2019
Figure 6 : Boehringer Ingelheim GmbH: Revenue Shares, by Region, 2019
Figure 7 : Roche: Annual Revenue, 2018 and 2019
Figure 8 : Roche: Revenue Share, by Product Category, 2019

 

List of Tables


Table 1 : Idiopathic Pulmonary Fibrosis Drug Sales, by Country, Through 2024
Table 2 : Main Symptoms of Idiopathic Pulmonary Fibrosis
Table 3 : Other Symptoms of Idiopathic Pulmonary Fibrosis
Table 4 : Key Drugs Marketed for IPF
Table 5 : Esbriet Drug Profile
Table 6 : Boehringer Ingelheim GmbH: IPF Product Portfolio
Table 7 : Roche: IPF Portfolio
Table 8 : Roche: IPF Pipeline Portfolio
Table 9 : Ofev Drug Profile
Table 10 : Sales of Esbriet for IPF, 2018-2024
Table 11 : Number of IDF Patients Using Esbriet, 2018-2024
Table 12 : Sales of Ofev for IPF, 2018-2024
Table 13 : Number of IPF Patients Using Ofev, 2018-2024
Table 14 : Phase III Pipeline Products in Development for IPF
Table 15 : Acronyms Used in This Report